Overview

The marketing authorisation for Onduarp has been withdrawn at the request of the marketing-authorisation holder.

български (BG) (630.81 KB - PDF)

View

español (ES) (540.23 KB - PDF)

View

čeština (CS) (592.53 KB - PDF)

View

dansk (DA) (576.08 KB - PDF)

View

Deutsch (DE) (544.29 KB - PDF)

View

eesti keel (ET) (523.65 KB - PDF)

View

ελληνικά (EL) (636.8 KB - PDF)

View

français (FR) (525.51 KB - PDF)

View

italiano (IT) (525.8 KB - PDF)

View

latviešu valoda (LV) (599.49 KB - PDF)

View

lietuvių kalba (LT) (554.08 KB - PDF)

View

magyar (HU) (583.99 KB - PDF)

View

Malti (MT) (593.57 KB - PDF)

View

Nederlands (NL) (523.66 KB - PDF)

View

polski (PL) (594.97 KB - PDF)

View

português (PT) (523.91 KB - PDF)

View

română (RO) (554.71 KB - PDF)

View

slovenčina (SK) (589.48 KB - PDF)

View

slovenščina (SL) (586.59 KB - PDF)

View

Suomi (FI) (524.68 KB - PDF)

View

svenska (SV) (583.76 KB - PDF)

View

Product information

български (BG) (4.78 MB - PDF)

View

español (ES) (1.58 MB - PDF)

View

čeština (CS) (3.16 MB - PDF)

View

dansk (DA) (1.55 MB - PDF)

View

Deutsch (DE) (1.49 MB - PDF)

View

eesti keel (ET) (1.39 MB - PDF)

View

ελληνικά (EL) (5.04 MB - PDF)

View

français (FR) (1.5 MB - PDF)

View

hrvatski (HR) (1.1 MB - PDF)

View

íslenska (IS) (561.49 KB - PDF)

View

italiano (IT) (1.46 MB - PDF)

View

latviešu valoda (LV) (3.58 MB - PDF)

View

lietuvių kalba (LT) (1.81 MB - PDF)

View

magyar (HU) (3.15 MB - PDF)

View

Malti (MT) (3.35 MB - PDF)

View

Nederlands (NL) (1.47 MB - PDF)

View

norsk (NO) (580.92 KB - PDF)

View

polski (PL) (3.44 MB - PDF)

View

português (PT) (1.47 MB - PDF)

View

română (RO) (1.87 MB - PDF)

View

slovenčina (SK) (3.3 MB - PDF)

View

slovenščina (SL) (3.26 MB - PDF)

View

Suomi (FI) (1.53 MB - PDF)

View

svenska (SV) (1.43 MB - PDF)

View

Latest procedure affecting product information: WS/0236

17/02/2014

icon globe

This medicine’s product information is available in all official EU languages.
Select 'available languages' to access the language you need.

 

Product information documents contain:

  • summary of product characteristics (annex I);
  • manufacturing authorisation holder responsible for batch release (annex IIA);
  • conditions of the marketing authorisation (annex IIB);
  • labelling (annex IIIA);
  • package leaflet (annex IIIB).

български (BG) (530.2 KB - PDF)

View

español (ES) (476.78 KB - PDF)

View

čeština (CS) (511.93 KB - PDF)

View

dansk (DA) (487.48 KB - PDF)

View

Deutsch (DE) (476.11 KB - PDF)

View

eesti keel (ET) (476.63 KB - PDF)

View

ελληνικά (EL) (536.96 KB - PDF)

View

français (FR) (487.46 KB - PDF)

View

íslenska (IS) (25.81 KB - PDF)

View

italiano (IT) (474.03 KB - PDF)

View

latviešu valoda (LV) (518.12 KB - PDF)

View

lietuvių kalba (LT) (517.38 KB - PDF)

View

magyar (HU) (528.6 KB - PDF)

View

Malti (MT) (527.28 KB - PDF)

View

Nederlands (NL) (475.98 KB - PDF)

View

norsk (NO) (19.76 KB - PDF)

View

polski (PL) (507.57 KB - PDF)

View

português (PT) (487.82 KB - PDF)

View

română (RO) (515 KB - PDF)

View

slovenčina (SK) (512.76 KB - PDF)

View

slovenščina (SL) (499.61 KB - PDF)

View

Suomi (FI) (487.61 KB - PDF)

View

svenska (SV) (476.49 KB - PDF)

View

Product details

Name of medicine
Onduarp
Active substance
Telmisartan
International non-proprietary name (INN) or common name
  • telmisartan
  • amlodipine
Therapeutic area (MeSH)
Hypertension
Anatomical therapeutic chemical (ATC) code
C09DB04

Pharmacotherapeutic group

Cardiovascular system

Therapeutic indication

Treatment of essential hypertension in adults:

Add on therapy

Onduarp is indicated in adults whose blood pressure is not adequately controlled on amlodipine.

Replacement therapy

Adult patients receiving telmisartan and amlodipine from separate tablets can instead receive tablets of Onduarp containing the same component doses.

Authorisation details

EMA product number
EMEA/H/C/002118
Marketing authorisation holder
Boehringer Ingelheim International GmbH

Binger Strasse 173
D-55216 Ingelheim am Rhein
Germany

Marketing authorisation issued
24/11/2011
Revision
2

Assessment history

Topics

This page was last updated on

Share this page